Jonathan T Lei - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jonathan T Lei

Showing results (31-40 of 50) with videos related to

Pageof 5

Sort By:

Molecular Cancer Therapeutics|May 23, 2024

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.

Cancer Research Communications|July 28, 2023

Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.

Oncogene|May 12, 2018

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targetsLeah A Gates, Guowei Gu, Yue Chen, et al.

Cell Reports. Medicine|August 1, 2025

Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.

Iscience|January 9, 2023

Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approachVarduhi Petrosyan, Lacey E Dobrolecki, Lillian Thistlethwaite, et al.

Cell Reports. Medicine|June 6, 2025

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, et al.

Cancer Cell|March 7, 2020

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast CancerZe-Yi Zheng, Meenakshi Anurag, Jonathan T Lei, et al.

Molecular Cancer Therapeutics|July 15, 2026

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor CombinationsAnh Minh Tran Huynh, Jonathan T Lei, Rachel Brough, et al.

Nature|June 3, 2016

Proteogenomics connects somatic mutations to signalling in breast cancerPhilipp Mertins, D R Mani, Kelly V Ruggles, et al.

Biorxiv : the Preprint Server for Biology|December 23, 2024

Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy ResponsesJonathan T Lei, Lacey E Dobrolecki, Chen Huang, et al.

Pageof 5

Search research articles

Showing results (31-40 of 50) with videos related to

Sort By:

Pageof 5

Molecular Cancer Therapeutics|May 23, 2024

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast CancerAnran Chen, Beom-Jun Kim, Aparna Mitra, et al.

Cancer Research Communications|July 28, 2023

Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Ze-Yi Zheng, Jonathan T Lei, et al.

Oncogene|May 12, 2018

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targetsLeah A Gates, Guowei Gu, Yue Chen, et al.

Cell Reports. Medicine|August 1, 2025

Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancerMatthew V Holt, Yongchao Dou, Meggie N Young, et al.

Iscience|January 9, 2023

Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approachVarduhi Petrosyan, Lacey E Dobrolecki, Lillian Thistlethwaite, et al.

Cell Reports. Medicine|June 6, 2025

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J Jaehnig, Aranzazu Fernandez-Martinez, Tanmayi D Vashist, et al.

Cancer Cell|March 7, 2020

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast CancerZe-Yi Zheng, Meenakshi Anurag, Jonathan T Lei, et al.

Molecular Cancer Therapeutics|July 15, 2026

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor CombinationsAnh Minh Tran Huynh, Jonathan T Lei, Rachel Brough, et al.

Nature|June 3, 2016

Proteogenomics connects somatic mutations to signalling in breast cancerPhilipp Mertins, D R Mani, Kelly V Ruggles, et al.

Biorxiv : the Preprint Server for Biology|December 23, 2024

Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy ResponsesJonathan T Lei, Lacey E Dobrolecki, Chen Huang, et al.

Pageof 5